Eli Lilly and Company Q2 2025 Earnings Call

Eli Lilly and Company Q2 2025 Earnings Call

• 2. Q2 2025 EARNINGS CALL ELI LILLY AND COMPANY

• 3. 2025 Q2 EARNINGS Introduction and Key Events Dave Ricks, Chair and Chief Executive Officer Q2 2025 Financial Results Lucas Montarce, Chief Financial Officer R&D Update Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer Question & Answer Session Agenda 3

• 4. 2025 Q2 EARNINGS Not for promotional use 4 Safe Harbor Provision and Other Information This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including healthcare reform. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's nonGAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated. The company undertakes no duty to update forward-looking statements except as required by applicable law.

• 5. 2025 Q2 EARNINGS Not for promotional use 5 Q2 2025 Summary Invest in Future Innovation Speed Life-Changing Medicines Delivered robust revenue growth of 38% driven by Key Products1 Lilly U.S. incretin analogs share of market increased to 57.0% of total prescriptions, with market growing 41% versus prior year Raised midpoint of revenue guidance by $1.5 billion for the full year Produced 1.6x more saleable incretin doses in 1H 2025 compared to 1H 2024 Closed acquisitions of SiteOne Therapeutics and Verve Therapeutics to expand pipeline 1 Key products include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound Note: Revenue growth rates reflect change vs. Q2 2024 Orforglipron delivered weight loss of more than 27 lbs in ATTAIN-1 Mounjaro demonstrated cardiovascular protection in SURPASS-CVOT Jaypirca met primary endpoint in H2H Phase 3 trial versus ibrutinib in CLL/SLL Deliver Revenue Growth

• 6. 2025 Q2 EARNINGS Not for promotional use 6 Strategic Deliverables RESEARCH & DEVELOPMENT $3.3B TOTAL REVENUE $15.6B INCRETIN SUPPLY Saleable doses produced in 1H 2025 vs. 1H 2024 • FDA approved updated label for Kisunla with new dosing in early symptomatic Alzheimer’s disease APPROVALS / LAUNCHES STUDY RESULTS $1.3B $0.7B DISTRIBUTED VIA DIVIDENDS DISTRIBUTED IN SHARE REPURCHASES Deliver Revenue Growth Invest in Future Innovation Invest in Current Portfolio Speed Life-Changing Medicines Return Capital to Shareholders 38% KEY PRODUCT REVENUE $10.4B 80% 23% MARKETING, SELLING & ADMINISTRATIVE $2.8B 30% NON-GAAP EARNINGS PER SHARE $6.31 61% Note: Total revenue, key product revenue, research and development, marketing, selling and administrative, and Non-GAAP EPS growth rates reflect change vs. Q2 2024 +1.6x • Launched 12.5 mg and 15.0 mg single-dose Zepbound vials exclusively through LillyDirect • Received positive CHMP opinion for Kisunla in the EU • Orforglipron delivered weight loss of more than 27 lbs (12.4%) in ATTAIN-1 and showed safety and tolerability consistent with injectable GLP-1 therapies • Mounjaro met the primary objective of non-inferiority versus Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight • Jaypirca met its primary endpoint in a H2H Phase 3 trial versus ibrutinib in CLL/SLL

• 7. 2025 Q2 EARNINGS Dollars in millions; except per share data Q2 2025 YoY Non-GAAP Adjusted Change GAAP Reported Adjustments Non-GAAP Adjusted TOTAL REVENUE $15,558 $ - $15,558 38% GROSS MARGIN 84.3% 0.7 pp 85.0% 3.0pp TOTAL OPERATING EXPENSE $6,243 $ - $6,243 25% OPERATING INCOME $6,867 $122 $6,989 63% OTHER INCOME (EXPENSE) $(91) $(98) $(189) NM EFFECTIVE TAX RATE 16.5% -- 16.5% -- NET INCOME $5,661 $18 $5,679 60% EPS $6.29 $0.02 $6.31 61% Acquired IPR&D Charge per share1 $0.14 $ - $0.14 0% Performance Margin2 45.1% 45.9% +6.6pp 1 Acquired IPR&D (in-process research and development) charge of $154 million (pre-tax). Numbers may not add due to rounding; NM = not meaningful Not for promotional use 7 Q2 Key Income Statement Measures (unaudited) 2 The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 20

• 8. 2025 Q2 EARNINGS Q2 2025 Amount Price FX Rate Volume Total CER U.S. $10,814 (8)% - 46% 38% 38% EUROPE $2,574 (2)% 6% 79% 83% 77% JAPAN $521 (0)% 5% 7% 13% 7% CHINA $466 3% (1)% 16% 18% 19% REST OF WORLD $1,182 (0)% (1)% (0)% (2)% (1)% TOTAL REVENUE $15,558 (6)% 1% 42% 38% 37% CER = price change + volume change Numbers may not add due to rounding Dollars in millions Not for promotional use 8 Price/Rate/Volume Effect on Revenue YTD 2025 Amount Price FX Rate Volume Total CER U.S. $19,304 (8)% - 50% 43% 43% EUROPE $4,963 (5)% 0% 79% 74% 74% JAPAN $923 (1)% 1% 11% 12% 11% CHINA $917 2% (1)% 18% 19% 20% REST OF WORLD $2,180 0% (3)% 6% 4% 7% TOTAL REVENUE $28,286 (6)% (0)% 47% 41% 41% Dollars in millions

• 9. 2025 Q2 EARNINGS Not for promotional use 9 Q2 2025 Update on Key Products MOUNJARO U.S. type 2 diabetes incretin analogs TRx SOM 42% and NBRx SOM 50% at end of Q2 2025 Increased TRx and NBRx SOM by 3pp and 5pp, respectively, vs. end of Q1 2025 International markets becoming a meaningful growth driver ZEPBOUND U.S. branded anti-obesity TRx SOM 66% and NBRx SOM 68% at end of Q2 2025 TRx SOM increased by 5pp and NBRx SOM decreased by 6pp vs. end of Q1 2025 NBRx SOM impacted by loss of access on CVS template plans effective 7/1/25 VERZENIO U.S. TRx SOM 40% at end of Q2 2025 U.S. TRx grew 4% vs. Q2 2024 International volume grew 18% vs. Q2 2024 JAYPIRCA Q2 2025 sales of $123M and TRx increased 85% vs. Q2 2024 EBGLYSS Q2 2025 sales of $87M and published results of ADmirable 24-week study in adults and adolescents with skin of color and atopic dermatitis OMVOH Q2 2025 sales of $75M and citrate-free formulation available KISUNLA Q2 2025 sales of $49M and currently launched in 13 countries OUS Key Product Highlights: $0 $2,000 $4,000 $6,000 $8,000 $10,000 $12,000 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2022 2023 2024 2025 Millions

• 10. 2025 Q2 EARNINGS 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0% 0 300 600 900 1,200 1,500 1,800 2,100 Not for promotional use 10 TOTAL PRESCRIPTIONS +41% in Q2 vs. PY NOVO SOM 42.5% LILLY SOM 57.0% Total Prescriptions 4 Week Rolling Average (thousands) Source: IQVIA weekly NPA total prescriptions, weekly data June 27, 2025; Incretin analogs market includes: injectable GLP-1s, oral GLP-1s and GLP1/GIP dual agonists U.S. Incretin Analogs Market Incretin Analogs Market Key Highlights: U.S. market grew 41% in Q2 vs. prior year and 13% vs. Q1 2025 Lilly share of market increased to 57.0%, +3.8pp vs. prior quarter Launched 12.5 mg and 15.0 mg singledose Zepbound vials via LillyDirect Zepbound CVS template plans access change as of 7/1/25 Zepbound has confirmed open access at 2 of 3 major PBMs

• 11. 2025 Q2 EARNINGS $1.9 $2.7 $2.0 $3.2 $5.1 $ in billions Dividend R&D* Capital Investments Business Development** Share Repurchase Growth Return * After tax ** Includes development milestones, closed acquisitions and cash outflows associated with equity investments 1H 2025 Capital Allocation Not for promotional use 11 Capital Allocation

• 12. 2025 Q2 EARNINGS Prior Updated Comments Strength of underlying business and updated foreign exchange rate expectations REVENUE $58.0 – $61.0 billion $60.0 – $62.0 billion PERFORMANCE MARGIN1 Increased to reflect updated revenue growth expectations (GAAP) 40.5% – 42.5% 42.0% – 43.5% (NON-GAAP) 41.5% – 43.5% 43.0% – 44.5% Decrease in net losses on investments in equity securities OTHER INCOME/(EXPENSE) (GAAP) $(850) – $(750) million $(750) – $(650) million (NON-GAAP) $(700) – $(600) million Unchanged TAX RATE Reflects anticipated third quarter charge as a result of recently enacted U.S. tax legislation (GAAP) (GAAP) Approx. 17% Approx. 19% (NON-GAAP) Approx. 17% Unchanged EARNINGS PER SHARE2 (GAAP) $20.17 – $21.67 $20.85 – $22.10 (NON-GAAP) $20.78 – $22.28 $21.75 – $23.00 1 The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative and asset impairment, restructuring and other special charges divided by revenue 2 2025 assumes shares outstanding of approximately 899.6 million FX assumptions of 1.14 (Euro), 149 (Yen) and 7.2 (Yuan) Not for promotional use 12 2025 Guidance

• 13. 2025 Q2 EARNINGS SURPASS-CVOT Topline Results Cardiovascular Protection (Primary Outcome) Weight Loss HbA1c Control Kidney Protection • Tirzepatide demonstrated non-inferiority vs. dulaglutide with an 8%1lower rate of MACE-3 events and a 16%2,3 lower rate of all-cause death • Tirzepatide reduced the risk of MACE-3 events by 28% and all-cause mortality by 39% vs. putative placebo4 • Tirzepatide demonstrated a 6.78 kg3,5 (14.95 lbs) greater reduction in body weight vs. dulaglutide at 36 months • Tirzepatide delivered a 0.83%3,6 greater reduction in A1C from mean baseline vs. dulaglutide at 36 months • Tirzepatide slowed eGFR decline by 3.543,7 ml/min/1.73 m2vs. dulaglutide in participants with high or very-high risk of CKD8at 36 months 1 Hazard ratio: 0.92, 95.3% CI: 0.83 to 1.01; 2 Hazard ratio: 0.84, 95.0% CI: 0.75 to 0.94; 3 Not controlled for multiplicity-adjusted type 1 error rate; 4 Based on a pre-specified indirect comparison analysis of matched patient-level data from the REWIND and SURPASS-CVOT studies; 5 Estimated treatment difference: -7.1%, 95.0% CI: -7.4 to -6.8; 695.0% CI: -0.88 to -0.78; 7 95.0% CI: 2.57 to 4.50; 8 Chronic kidney disease The safety of tirzepatide and dulaglutide were generally consistent with their established profiles Not for promotional use 13

• 14. 2025 Q2 EARNINGS Not for promotional use 14 Orforglipron ATTAIN-1 Topline Results Approximately 40% of participants taking the highest dose of orforglipron achieved body weight reductions of greater than or equal to 15%1 Once-daily oral pill reduced weight by an average of 27.3 lbs (12.4%) at the highest dose Key Highlights: Approximately 60% of participants taking the highest dose of orforglipron achieved body weight reductions of greater than or equal to 10%1 Body Weight Change at 72 Weeks BASELINE WEIGHT: 103.2 kg Placebo Orforglipron 6 mg Orforglipron 12 mg Orforglipron 36 mg -1.0 kg -8.0 kg -9.4 kg -12.4 kg -7.8% -9.3% -12.4% -0.9% 1 Superiority test was adjusted for multiplicity Lilly plans to submit orforglipron to regulatory agencies by year-end

• 15. 2025 Q2 EARNINGS Not for promotional use 15 Orforglipron 36 mg Orforglipron 12 mg Orforglipron 6 mg Placebo Nausea (%) 10.4% 28.9% 35.9% 33.7% Constipation (%) 9.3% 21.7% 29.8% 25.4% Diarrhea (%) 9.6% 21.0% 22.8% 23.1% Vomiting (%) 3.5% 13.0% 21.4% 24.0% Discontinuation Rates due to Adverse Events Tolerability Data The overall safety profile of orforglipron in ATTAIN-1 was consistent with the established GLP-1 receptor agonist class. Treatment discontinuations due to adverse events were low and consistent with the injectable GLP-1 class. 5.1% 7.7% 10.3% 6 mg 12 mg 36 mg Orforglipron ATTAIN-1 Safety & Tolerability

• 16. 2025 Q2 EARNINGS Not for promotional use 16 PHASE 1 PHASE 2 PHASE 3 1China development with Innovent for Obesity (approved) and T2DM (reg review) PTK7 ADC Cancer PCSK9 EDITOR (VERVE-102) ASCVD NAV 1.8 INH (STC-004)Pain GS INSULIN RECEPTOR AGONIST II Diabetes GGG TRI-AGONIST III CMH ANGPTL3 EDITOR (VERVE-201) ASCVD TARGETS UNDISCLOSED Nine Additional NMEs VEPUGRATINIB (FGFR3 SELECTIVE) Cancer SNCA siRNANeurodegeneration SMARCA2 (BRM) Cancer SARM1 INHIBITOR Neurodegeneration PNPLA3 siRNA MASLDPI3Kα INH (STX-478) Cancer PAN KRAS Cancer NECTIN-4 ADC 2 Cancer NECTIN-4 ADC 1 Cancer MAPT siRNA Neurodegeneration MACUPATIDE CMH LA-ANP Heart Failure KRAS G12D Cancer INTEGRIN α5β1 CMH GS INSULIN RECEPTOR AGONIST Diabetes GIPR AGONIST LA CMH GIP/GLP-1 COAGONIST III CMH FXR AG (FXR314) Immunology FRa ADC Cancer AT2R ANTAGONIST Pain ANTI-VEGF GENE THERAPY Vestibular Schwannoma [Ac-225]-PSMA-62 Prostate Cancer TIRZEPATIDE MASLDTIRZEPATIDE Higher Doses MORF-057 Crohn’s Disease GBA1 GENE THERAPY Gaucher Disease Type 1 ELTREKIBART Ulcerative Colitis CD19 ANTIBODY Rheumatoid Arthritis NISOTIROSTIDE Diabetes SOLBINSIRAN CVD SIMEPDEKINRA Psoriasis P2X7 INHIBITORPain OTOF GENE THERAPY Hearing Loss OCADUSERTIB Rheumatoid Arthritis NAPERIGLIPRON (GLP-1R NPA II) Obesity MUVALAPLINASCVD MORF-057 Ulcerative Colitis MEVIDALEN AD Symptomatic MAZDUTIDE1 Obesity GRN GENE THERAPY Frontotemporal Dementia GBA1 GENE THERAPY Parkinson’s Disease EPIREGULIN Ab Pain ELTREKIBART Hidradenitis SuppurativaELORALINTIDE Obesity CD19 ANTIBODY Multiple Sclerosis BIMAGRUMAB Obesity TIRZEPATIDE Type 1 Diabetes RETATRUTIDE CLBP ORFORGLIPRON Hypertension OLOMORASIB Adj KRAS G12C+ NSCLC (unresected) TIRZEPATIDE MMO TIRZEPATIDE CV Outcomes SELPERCATINIB Adjuvant RET+ NSCLC RETATRUTIDE Diabetes RETATRUTIDE CV / Renal Outcomes PIRTOBRUTINIB R/R MCL Monotherapy PIRTOBRUTINIB R/R CLL Combination PIRTOBRUTINIB 1L CLL Monotherapy ORFORGLIPRON Obstructive Sleep Apnea ORFORGLIPRON Diabetes OLOMORASIB Adj KRAS G12C+ NSCLC (resected) OLOMORASIB 1L KRAS G12C+ NSCLC (PD-L1 high) LEBRIKIZUMAB CRSwNP LEBRIKIZUMAB AR (perennial allergens) IXEKIZUMAB + TIRZEPATIDE PsoriasisIXEKIZUMAB + TIRZEPATIDE PsA IMLUNESTRANT Adjuvant Breast Cancer DONANEMAB Preclinical Alzheimer’s Disease ABEMACICLIB MBC Sequencing RETATRUTIDE Obesity, OA, OSA REMTERNETUG Alzheimer’s Disease ORFORGLIPRON Obesity OLOMORASIB 1L KRAS G12C+ NSCLC (All PD-L1) LEPODISIRAN ASCVD TIRZEPATIDE Heart Failure pEF INSULIN EFSITORA ALFA Diabetes IMLUNESTRANT ER+ HER2- mBC REG REVIEW APPROVED NME NILEX UPDATES SINCE APRIL 29, 2025 REMOVAL ADDITION OR MILESTONE ACHIEVED MAZISOTINE Pain KV1.3 ANTAGONIST PsoriasisSCAP siRNA MASLD ITACONATE MIMETIC Immunology Lilly Select NME and NILEX Pipeline August 5, 2025

• 17. 2025 Q2 EARNINGS NEW SINCE LAST UPDATE Not for promotional use 17 Potential Key Events 2025 1 Non-small cell lung cancer; 2 Atherosclerotic cardiovascular disease; 3 Osteoarthritis; 4 Metabolic dysfunction-associated steatotic liver disease; 5 Bendamustine plus Rituximab PHASE 3 INITIATIONS Orforglipron for hypertension and overweight or obesity Olomorasib for resected adjuvant NSCLC1 Muvalaplin for ASCVD2 Retatrutide for chronic low back pain and overweight or obesity Olomorasib for unresected NSCLC1 Tirzepatide for type 1 diabetes Orforglipron for OA3 pain of the knee and overweight or obesity Retatrutide and Tirzepatide for MASLD4 + + + + + REGULATORY SUBMISSIONS Insulin efsitora alfa for type 2 diabetes [US / EU + / J] Orforglipron for obesity [US/EU/J] Tirzepatide for cardiovascular outcomes [US] Pirtobrutinib CLL full approval [US +] Pirtobrutinib for 1L CLL [US/EU] Tirzepatide for Pediatric and Adolescent type 2 diabetes [US +/ EU +] PHASE 3 DATA DISCLOSURES Orforglipron for obesity [ATTAIN-1 + / 2] Orforglipron for type 2 diabetes [ACHIEVE-1 + /2/3/5] Tirzepatide cardiovascular outcomes [SURPASS-CVOT] Pirtobrutinib 1L CLL vs. BR5 [BRUIN CLL-313] Pirtobrutinib 1L CLL vs. ibrutinib [BRUIN CLL-314] Retatrutide for OA3 pain of the knee and overweight or obesity [TRIUMPH-4] REGULATORY ACTIONS Mirikizumab for Crohn’s disease [US + / EU + / J +] Tirzepatide for HFpEF [US - /EU] Imlunestrant ER+, HER2- mBC [US/J] Pirtobrutinib for CLL full approval [US / EU + / J] Donanemab for early Alzheimer’s disease [EU] + + + + +

• 18. 2025 Q2 EARNINGS Not for promotional use 18 Supplemental Slides

• 19. 2025 Q2 EARNINGS * Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable) NM = not meaningful Not for promotional use 19 2025 Income Statement – Reported Dollars in millions; except per share data Q2 2025 Change TOTAL REVENUE $15,558 38% GROSS MARGIN 84.3% 3.5pp TOTAL OPERATING EXPENSE* $6,243 15% OPERATING INCOME $6,867 85% OPERATING MARGIN 44.1% 11.2pp OTHER INCOME (EXPENSE) $(91) (54%) EFFECTIVE TAX RATE 16.5% 0.9pp NET INCOME $5,661 91% EPS $6.29 92%

• 20. 2025 Q2 EARNINGS Not for promotional use 20 EPS Reconciliation Q2 2025 Q2 2024 % Change $6.29 $3.28 92% EARNINGS PER SHARE (REPORTED) – 0.38 NM ASSET IMPAIRMENT, RESTRUCTURING AND OTHER SPECIAL CHARGES (0.09) 0.14 (164%) NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES AMORTIZATION OF INTANGIBLE ASSETS 0.11 0.12 (8%) $6.31 $3.92 61% EARNINGS PER SHARE (NON-GAAP) ACQUIRED IPR&D $0.14 $0.14 0% Numbers may not add due to rounding; see slide 21 for more details on these adjustments; NM = not meaningful

• 21. 2025 Q2 EARNINGS Q2 2025 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE: • amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $121.8 million (pre-tax), or $0.11 per share (after-tax) • net gains on investments in equity securities totaling $98.4 million (pre-tax), or ($0.09) per share (after-tax) Q2 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE: • amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $139.1 million (pre-tax), or $0.12 per share (after-tax) • net losses on investments in equity securities totaling $147.7 million (pre-tax), or $0.14 per share (after-tax). • asset impairment, restructuring and other special charges totaling $435.0 million (pre-tax), or $0.38 per share (after-tax). Not for promotional use 21 Q2 Non-GAAP Adjustments

• 22. 2025 Q2 EARNINGS 0 200 400 600 800 1000 1200 1400 0% 10% 20% 30% 40% 50% 60% 70% Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 13 Wk RA TRx Market Volume (000s) 13 Wk RA TRx SOM U.S. TRx SOM and Market Volume Source: IQVIA NPA TRx 3MMA, weekly data June 27, 2025; RA = rolling average TRx data is representative of the injectable incretin type 2 diabetes market Mounjaro $ in Millions U.S. sales were $3.3 billion International sales were $1.9 billion Market Not for promotional use 22 Q2 2025 Mounjaro Sales Increased $2.1B $1,807 $3,091 $3,113 $3,530 $3,842 $5,199 Q1 Q2 Q3 Q4 2024 2025

• 23. 2025 Q2 EARNINGS 0 100 200 300 400 500 600 700 0% 10% 20% 30% 40% 50% 60% 70% 80% Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 13 Wk RA TRx Market Volume (000s) 13 Wk RA TRx SOM U.S. TRx SOM and Market Volume Source: IQVIA NPA TRx 3MMA, weekly data June 27, 2025; RA = rolling average TRx data is representative of the branded anti-obesity market Zepbound $ in Millions Market Not for promotional use 23 Q2 2025 Zepbound Sales Increased $2.1B 1 Japan and Canada marketing authorization approved for obesity under the brand name Zepbound U.S. sales were $3.4 billion International sales were $1.5 million1 $517 $1,243 $1,258 $1,907 $2,312 $3,381 Q1 Q2 Q3 Q4 2024 2025

• 24. 2025 Q2 EARNINGS 6 7 8 9 10 11 0% 10% 20% 30% 40% 50% 60% Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 13 Wk RA TRx Market Volume (000s) 13 Wk RA TRx SOM U.S. sales increased 8% International sales increased 19% U.S. TRx SOM and Market Volume Market Verzenio $ in Millions Not for promotional use 24 Q2 2025 Verzenio Sales Increased 12% Source: IQVIA NPA TRx 3MMA, weekly data June 27, 2025; RA = rolling average $1,050 $1,332 $1,369 $1,555 $1,159 $1,489 Q1 Q2 Q3 Q4 2024 2025

• 25. 2025 Q2 EARNINGS Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Apr 2023 Aug 2025 Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population) 3 1736 A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Alzheimer's Disease NCT04437511 May 2024 May 2025 Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E) 3 1100 A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) Alzheimer's Disease NCT05738486 May 2028 July 2028 Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) 3 1500 A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Alzheimer's Disease NCT05508789 Nov 2027 Nov 2027 Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS) 3 2996 A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) Alzheimer's Disease NCT05026866 Not for promotional use 25 Select Trials – Donanemab * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025

• 26. 2025 Q2 EARNINGS Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Jun 2024 Aug 2027 Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) 3 874 A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) NCT04975308 Breast Neoplasms 3 8000 Invasive Disease-Free Survival (IDFS) Oct 2027 Mar 2032 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) NCT05514054 Breast Neoplasms Not for promotional use 26 Select Trials – Imlunestrant * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025

• 27. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 27 Select Trials – Lebrikizumab Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Dec 2025 Dec 2026 Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline 3 360 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1) NCT05559359 Atopic Dermatitis Dec 2027 Apr 2029 Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs) 3 310 A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2) NCT05735483 Atopic Dermatitis Sep 2025 Aug 2026 Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) ≥75% Reduction in EASI Score for Mono Cohort 3 301 A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (ADvance-Asia) NCT06280716 Atopic Dermatitis Oct 2025 Feb 2027 Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16 3 450 A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) Perennial Allergic Rhinitis (PAR) NCT06339008 Jul 2026 Sep 2026 Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline 3 206 A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch) Atopic Hand and Foot Dermatitis NCT06921759 Oct 2026 Feb 2027 Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity 3 510 A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) NCT06338995

• 28. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 28 Select Trials – Lepodisiran Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Mar 2029 Mar 2029 Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint 3 16700 A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Atherosclerotic Cardiovascular Disease (ASCVD)1 NCT06292013 1 Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

• 29. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 29 Select Trials – Mirikizumab Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Nov 2024 Dec 2026 Percentage of Participants Achieving Endoscopic Response 3 778 A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2) NCT04232553 Crohn's Disease May 2028 May 2028 Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction 3 290 Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD) NCT06937099 Crohn's Disease 3 1063 Percentage of Participants in Clinical Remission Jul 2026 Dec 2027 A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3) NCT03519945 Ulcerative Colitis Apr 2028 Apr 2028 Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction 3 350 Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) NCT06937086 Ulcerative Colitis

• 30. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 30 Select Trials –Olomorasib Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Oct 2026 Oct 2029 Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE) 3 1016 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01) Carcinoma, NonSmall-Cell Lung NCT06119581 May 2029 Feb 2032 Part A: Disease-Free Survival (DFS) by Investigator Assessment 3 700 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02) Carcinoma, NonSmall-Cell Lung NCT068905981 Apr 2027 Apr 2027 Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy 1|2 540 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Carcinoma, NonSmall-Cell Lung NCT049566402 1 Also lists AstraZeneca; 2 Also lists Merck Sharp & Dohme LLC

• 31. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 31 Select Trials –Orforglipron Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Sep 2025 Sep 2025 Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c) 3 520 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT2 Inhibitor (ACHIEVE-5) NCT06109311 Type 2 Diabetes 3 1576 Change from Baseline in Hemoglobin A1c (HbA1c) Sep 2025 Sep 2025 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3) NCT06045221 Type 2 Diabetes Sep 2025 Jan 2026 Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death] 3 2749 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) NCT05803421 Type 2 Diabetes 3 888 Change from Baseline in Hemoglobin A1c: (HbA1c) Sep 2025 Sep 2025 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2) NCT06192108 Type 2 Diabetes 3 974 Number of Participants Allocated to Each ISA Sep 2027 Sep 2027 A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension) NCT06948422 Hypertension 3 236 Mean Percent Change in Body Weight Jun 2025 July 2025 A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J) NCT05931380 Obesity

• 32. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 32 Select Trials –Orforglipron (Cont.) Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** 3 3000 Mean Percent Change from Baseline in Body Weight Jul 2025 Jul 2027 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) NCT05869903 Obesity 3 1500 Mean Percent Change from Baseline in Body Weight Aug 2025 Aug 2025 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) NCT05872620 Obesity Jan 2026 Jan 2026 Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5 3 300 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) NCT06584916 Obesity 3 125 Percent Change from Baseline in Body Mass Index (BMI) Feb 2027 Mar 2027 A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities NCT06672939 Obesity 3 600 Change from Baseline in Hemoglobin A1c (HbA1c) Jan 2027 Aug 2027 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes NCT06972472 Obesity 3 600 Percent Change from Baseline in Body Weight Jan 2027 Aug 2027 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity NCT06972459 Obesity

• 33. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 33 Select Trials –Orforglipron (Cont.) Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** 3 600 Change from Baseline in Apnea-Hypopnea Index (AHI) Nov 2026 Jan 2027 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) NCT06649045 OSA Dec 2025 Dec 2025 Percent Change from Baseline in Visceral Adipose Tissue (VAT) 1 120 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight NCT06824051 Obesity

• 34. 2025 Q2 EARNINGS Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 34 Select Trials – Pirtobrutinib Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Aug 2023 May 2027 Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) 3 238 Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321) Chronic Lymphocytic Leukemia NCT04666038 Jul 2025 Aug 2026 To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B) 3 309 A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) Chronic Lymphocytic Leukemia NCT05023980 Apr 2026 Jan 2027 To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B) 3 600 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322) Chronic Lymphocytic Leukemia NCT04965493 Jun 2025 Jan 2028 Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1 3 662 A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL – 314) Chronic Lymphocytic Leukemia NCT05254743 Jan 2027 Apr 2028 To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL) 3 500 Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321) Lymphoma, Mantle-Cell NCT04662255 Dec 2026 Feb 2027 Ph. 1 -Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration 1|2 58 A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia Immune Thrombocytopenia (ITP) NCT06721013 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

• 35. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 35 Select Trials – Remternetug Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Apr 2024 Mar 2026 Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo 3 1667 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) Alzheimer's Disease NCT05463731 Apr 2029 Oct 2030 Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR) 3 1400 A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) Alzheimer's Disease NCT06653153

• 36. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 36 Select Trials – Retatrutide Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** 3 2300 Percent Change From Baseline in Body Weight Apr 2026 May 2026 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) NCT05929066 Obesity 3 1000 Percent Change from Baseline in Body Weight May 2026 May 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) NCT05929079 Obesity 3 1800 Percent Change from Baseline in Body Weight Apr 2026 May 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) NCT05882045 Obesity Dec 2025 Dec 2025 Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score 3 405 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4) NCT05931367 Obesity 3 10000 Time to First Occurrence of Composite Endpoints Feb 2029 Feb 2029 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) NCT06383390 Obesity

• 37. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 37 Select Trials – Retatrutide (Cont.) Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** 3 800 Percent Change from Baseline in Body Weight Dec 2026 Dec 2026 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) NCT06662383 Obesity 3 643 Percent Change from Baseline in Body Weight Apr 2028 Apr 2028 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6) NCT06859268 Obesity 3 480 Change from Baseline in Hemoglobin A1c (HbA1c) Jan 2026 Feb 2026 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) NCT06354660 Type 2 Diabetes 3 320 Change from Baseline in Hemoglobin A1c (HbA1c) Sep 2026 Oct 2026 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) NCT06297603 Type 2 Diabetes 3 1250 Change from Baseline in Hemoglobin A1c (HbA1c) Aug 2026 Jan 2027 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) NCT06260722 Type 2 Diabetes

• 38. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 38 Select Trials – Retatrutide (Cont.) Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Sep 2027 Sep 2027 Percent Change from Baseline in Body Weight | Change from Baseline in Pain Intensity Per Numeric Rating Scale 3 586 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093 Obesity Nov 2025 Nov 2025 Change from Baseline in Glomerular Filtration Rate (mGFR) 2 146 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Chronic Kidney Disease NCT05936151 May 2026 May 2026 Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL) 1 78 A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia Type 2 Diabetes Mellitus NCT06982846 Nov 2026 Nov 2026 Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo 1 95 A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus NCT06982859 Diabetes Mellitus

• 39. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 39 Select Trials – Retevmo Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** May 2023 Feb 2026 Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) 3 291 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Medullary Thyroid Cancer NCT04211337 May 2023 Jun 2026 Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab) 3 261 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) Non-Small Cell Lung Cancer NCT04194944 Feb 2025 Feb 2026 Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment 1|2 857 A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Non-Small Cell Lung Cancer NCT03157128 May 2026 May 2028 Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population 3 152 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) Carcinoma, NonSmall-Cell Lung NCT04819100

• 40. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 40 Select Trials – Taltz Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** Dec 2025 May 2026 Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction 3 250 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO) NCT06588283 Psoriasis Apr 2026 Aug 2026 Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction 3 250 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA) NCT06588296 Psoriatic Arthritis

• 41. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 41 Select Trials – Tirzepatide Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** May 2026 May 2026 Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period 3 400 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN) NCT06047548 Obesity 3 150 Percent Change from Baseline in Body Mass Index (BMI) May 2026 Jul 2029 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS) NCT06075667 Obesity 3 300 Percent Change from Baseline in Body Mass Index (BMI) May 2027 Jun 2027 A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) NCT06439277 Obesity Oct 2027 Oct 2027 Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events) 3 15374 A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) NCT05556512 Obesity

• 42. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 42 Select Trials – Tirzepatide (Cont.) Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** 2 350 Percent Change From Baseline in Body Weight Jan 2026 Oct 2026 A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity NCT06037252 Type 2 Diabetes Sep 2026 Oct 2026 Change from Baseline in Kidney Oxygenation in Participants With or Without T2D 2 140 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD) NCT05536804 CKD 3 905 Change from Baseline in Hemoglobin A1c (HbA1c) May 2027 May 2027 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight NCT06914895 Type 1 Diabetes 3 465 Change from Baseline in Hemoglobin A1c (HbA1c) Apr 2027 Dec 2027 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight NCT06962280 Type 1 Diabetes

• 43. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 43 Select Trials – Verzenio Completion Primary Completion Study Indication* Title Phase Patients Primary Outcome** 3 5637 Invasive Disease-Free Survival (IDFS) Mar 2020 May 2029 Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) NCT03155997 Breast Cancer 1 3 368 Progression-Free Survival (PFS) Feb 2024 Feb 2026 Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch) NCT05169567 Breast Neoplasm 1 Also lists NSABP Foundation Inc

• 44. 2025 Q2 EARNINGS Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Apr 2026 Jan 2027 Percent Change from Baseline in Body Weight 2 240 A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Bimagrumab NCT06643728 Obesity Oct 2026 Jan 2027 Percent Change from Baseline in Body Weight 2 180 A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes Bimagrumab NCT06901349 Obesity Apr 2026 Apr 2026 Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Bimagrumab NCT07030127 Healthy A Study of LY3985863 in Healthy Participants 1 24 May 2025 Sep 2025 Percent Change from Baseline in Body Weight 2 263 A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight Eloralintide NCT06230523 Obesity Jun 2026 Aug 2026 Percent Change from Baseline in Body Weight 2 350 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Eloralintide NCT06603571 Obesity Aug 2025 Sep 2025 Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration 1 36 A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight Eloralintide NCT06916091 Obesity * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 44 Select Trials – Early Phase Cardiometabolic Health

• 45. 2025 Q2 EARNINGS Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 45 Select Trials – Early Phase Cardiometabolic Health (Cont.) Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Jul 2026 Jul 2026 Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration 1 302 A Study of LY3537031 in Overweight, Obese, and Healthy Participants NCT06606106 Healthy GIP/GLP-1 Coagonist III Oct 2025 Oct 2025 Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration 1 70 A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) NCT06280703 Healthy GS Insulin Receptor Agonist Dec 2025 Dec 2025 Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration LA-ANP NCT06148272 Healthy A Study of LY3971297 in Healthy Participants 1 225 Nov 2025 Nov 2025 Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Macupatide NCT06557356 Obesity A Study of LY3532226 in Participants With Obesity 1 129 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

• 46. 2025 Q2 EARNINGS Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Dec 2026 Jan 2027 Change from Baseline in Hemoglobin A1c (HbA1c) 2 240 A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Nisotirostide NCT06897475 Type 2 Diabetes Apr 2026 Sep 2026 Percent Change from Baseline in Body Weight 2 275 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight NCT06683508 Obesity Naperiglipron (GLP-1R NPA II) Oct 2026 Oct 2026 Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration 1 176 A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Metabolic Dysfunctionassociated Steatotic Liver Disease (MASLD) PNPLA3 siRNA NCT05395481 Mar 2027 Mar 2027 Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) 1 36 Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia Hypercholester olemia NCT06451770 ANGPTL3 EDITOR(VERVE-201) Aug 2026 Aug 2026 Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) 1 36 A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease Heterozygous Familial Hypercholester olemia NCT06164730 PCSK9 EDITOR (VERVE-102) Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 46 Select Trials – Early Phase Cardiometabolic Health * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

• 47. 2025 Q2 EARNINGS Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Aug 2027 Aug 2028 Cumulative Number of New T1 GadoliniumEnhancing (GdE) Lesions 2 200 A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis Multiple Sclerosis CD19 Antibody NCT06220669 Feb 2026 Sep 2026 Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP) 2 40 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis Rheumatoid Arthritis CD19 Antibody NCT06859294 Jul 2025 Aug 2025 Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 2 220 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis NCT06602219 Plaque Psoriasis SIMEPDEKINRA (DC-853) Oct 2025 Jul 2026 Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) 2 350 A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Eltrekibart NCT06046729 Dec 2027 Sep 2028 Percentage of Participants Achieving Clinical Remission 2 140 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis Eltrekibart NCT06598943 Not for promotional use 47 Select Trials – Early Phase Immunology Source: clinicaltrials.gov, July 28, 2025 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

• 48. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 48 Select Trials – Early Phase Immunology (Cont.) Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Nov 2024 Aug 2026 Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS) 2 282 A Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC (EMERALD-2) Ulcerative Colitis MORF-057 NCT05611671 Nov 2026 Aug 2028 Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD) 2 210 A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET) MORF-057 NCT06226883 Crohn's Disease Feb 2026 Jul 2026 Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP) 2 380 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Rheumatoid Arthritis Ocadusertib NCT05848258 1 1 Also lists Rigel Pharmaceuticals

• 49. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 49 Select Trials – Early Phase Neurodegeneration Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Aug 2029 Aug 2029 AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery device) 1|2 27 Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma Vestibular Schwannoma NCT06517888 Anti-VEGF Gene Therapy Dec 2030 Dec 2030 Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) 1|2 20 Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) Parkinson’s Disease GBA1 Gene Therapy NCT04127578 Oct 2030 Oct 2030 Incidence and severity of Treatmentemergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) 1|2 15 A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) GBA1 Gene Therapy NCT05487599 Gaucher Disease Apr 2030 Apr 2030 Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation 1|2 30 Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM) Frontotemporal Dementia GRN Gene Therapy NCT04408625

• 50. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 50 Select Trials – Early Phase Neurodegeneration (Cont.) Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Feb 2027 Feb 2027 Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration 1 32 A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease Alzheimer’s Disease MAPT siRNA NCT06297590 Aug 2026 Aug 2026 Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method 2 300 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Alcohol Use Disorder Mazdutide NCT06817356 Dec 2025 Jan 2026 Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) 2 300 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease Alzheimer’s Disease Mevidalen NCT06538116 1|2 14 Frequency of Adverse Events (AEs) Oct 2028 Oct 2028 Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss Sensorineural Hearing Loss, Bilateral OTOF Gene Therapy NCT05821959 1 108 Incidence of Serious Adverse Events (SAEs) May 2029 May 2029 A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease (PROSPECT) Parkinson’s Disease SNCA siRNA NCT06565195

• 51. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 51 Select Trials – Early Phase Oncology Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Sep 2027 Dec 2032 Maximum tolerated dose (MTD), Phase 1a: Incidence of dose limiting toxicities (DLTs) 1 142 [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL) 225Ac-PSMA-62 NCT06229366 Prostate Cancer Jun 2027 Jun 2027 Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs) 1 535 A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1) Urinary Bladder Neoplasms NCT05614739 VEPUGRATINIB (FGFR3 SELECTIVE) Feb 2027 Apr 2027 Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156, Number of participants with dose-limiting toxicities (DLTs) 1 360 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Ovarian Neoplasms NCT06400472 Fra ADC (FOLR1 ADC) Mar 2029 Mar 2029 Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration 1 570 A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01) Pancreatic Ductal Adenocarcinoma KRAS G12D NCT06586515 Mar 2027 Mar 2027 Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs) 1 490 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (EXCEED) Metastatic Solid Tumor Nectin-4 ADC 1 NCT06238479

• 52. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 52 Select Trials – Early Phase Oncology (Cont.) Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Jan 2030 Jan 2030 Number of Participants with Dose-limiting Toxicities (DLTs) 1 750 A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors Pancreatic Ductal Adenocarcinoma PAN KRAS NCT06607185 Oct 2027 Oct 2027 Phase 1a: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) 1 340 A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Metastatic Solid Tumor SMARCA2 (BRM) NCT06561685 Feb 2027 Feb 2029 Number of participants who experience at least 1 Dose Limiting Toxicity (DLT) 1|2 720 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors PI3Kα INH (STX-478) NCT05768139 Breast Cancer Jul 2030 Jul 2030 Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408 1 240 A Study of LY4175408 in Participants With Advanced Cancer Carcinoma, NonSmall-Cell Lung PTK7 ADC NCT07046923

• 53. 2025 Q2 EARNINGS * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 28, 2025 Not for promotional use 53 Select Trials – Early Phase Pain Completion Primary Completion Molecule Study Indication* Title Phase Patients Primary Outcome** Sep 2025 Sep 2025 Part 1: Percentage of Total Radioactive Dose in Urine and Fecal Excretion AT2R Antagonist NCT07039045 Healthy A Study of [14C]-LY4065967 in Healthy Participants 1 16 Jun 2026 Sep 2026 Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) 2 450 Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Neuropathic Pain Epiregulin Ab NCT06568042

• 54. 2025 Q2 EARNINGS Not for promotional use 54 Trademarks All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.